ALKS · Alkermes plc. · Webcasts, Transcripts & Audio
$41.75
+1.21 (+2.98%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$6.74B
Shares
167.76M
Volume · Oct 2
2.42M
Avg daily vol (3M)
1.81M
Alkermes plc. Webcasts
Earnings calls, investor updates, investor days and conferences for Alkermes plc. (ALKS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼14.2%
$252.36M
−$63.97M
'22 Q3
22-11-02
▼6.1%
$304.67M
−$28.25M
'22 Q4
23-02-16
▲3.2%
$287.60M
−$41.84M
'23 Q1
23-04-26
▲123.5%
$617.40M
$237.06M
'23 Q2
23-07-26
▲51%
$380.94M
$47.76M
'23 Q3
23-10-25
▲23.9%
$377.48M
$112.78M
'23 Q4
24-02-15
▲21.8%
$350.37M
$36.83M
'24 Q1
24-05-01
▼35.4%
$399.13M
$91.36M
'24 Q2
24-07-24
▼0.7%
$378.14M
$92.38M
'24 Q3
24-10-24
▲13.9%
$429.99M
$146.50M
'24 Q4
25-02-12
▼12.5%
$306.51M
$22.46M
'25 Q1
25-05-01
▼2.1%
$390.66M
$87.10M
'25 Q2
25-07-29
▲4.2%
$394.19M
$82.76M
'25 Q3
25-10-22
▼10.6%
$384.55M
$49.34M
'25 Q4
26-02-25
▲28.2%
$392.91M
−$66.48M
'26 Q1
26-05-05
LATEST
▲27%
$496.01M
$501,000
'26 Q2
26-07-28
Earnings call
FY26 · Q2
2026-07-28
Alkermes plc. (ALKS) Q2 2026 Earnings Call Transcript
Confident tone
Orexin franchise / pipeline leadership
ADHD program (ALK7290)
LumeRise / Avadel integration
Revenue
$496.01M
▲ 27% YoY Diluted EPS
$0.00
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-10
Alkermes plc. (ALKS) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Alkermes plc. (ALKS) Q1 2026 Earnings Call Transcript
Confident tone
Avadel acquisition and LUMRYZ integration
ADHD opportunity
Financial guidance and gross-to-net
Revenue
$392.91M
▲ 28.2% YoY Diluted EPS
$-0.40
▼ 407.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Alkermes plc. (ALKS) Q4 2025 Earnings Call Transcript
Confident tone
Elixorexant (orexin 2 receptor agonist) development
VIVITROL potential generic entry in 2027
Orexin pipeline beyond elixorexant (ALKS 4510, ALKS 7290)
Revenue
$384.55M*
▼ 10.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-22
Alkermes plc. (ALKS) Q3 2025 Earnings Call Transcript
Confident tone
Orexin Platform / Alixorexton
Proprietary Product Portfolio
Financial Performance and Guidance Raise
Revenue
$394.19M
▲ 4.2% YoY Diluted EPS
$0.49
▼ 10.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
Alkermes plc. (ALKS) Q2 2025 Earnings Call Transcript
Confident tone
Alixorexton / Vibrance 1 Phase II results
Commercial portfolio growth
Phase III preparation and dosing
Revenue
$390.66M
▼ 2.1% YoY Diluted EPS
$0.52
▼ 1.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Alkermes plc. (ALKS) Q1 2025 Earnings Call Transcript
Positive tone
ALKS 2680 Phase 2 orexin program (Vibrance-1 and Vibrance-2)
Commercial performance of proprietary products
Macroeconomic and policy landscape (tariffs, Medicaid, FDA)
Revenue
$306.51M
▼ 12.5% YoY Diluted EPS
$0.13
▼ 38.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-12
Alkermes plc. (ALKS) Q4 2024 Earnings Call Transcript
Confident tone
ALKS 2680 Orexin Program
LYBALVI Growth and Competition
Financial Performance and Profitability
Revenue
$429.99M*
▲ 13.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-24
Alkermes plc. (ALKS) Q3 2024 Earnings Call Transcript
Confident tone
Proprietary product growth (VIVITROL, ARISTADA, LYBALVI)
Operating efficiency and profitability / cost discipline
ALKS 2680 orexin 2 receptor agonist program
Revenue
$378.14M
▼ 0.7% YoY Diluted EPS
$0.55
▲ 96.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-24
Alkermes plc. (ALKS) Q2 2024 Earnings Call Transcript
Confident tone
ALKS 2680 Orexin program
LYBALVI growth and access
Proprietary product portfolio performance
Revenue
$399.13M
▼ 35.4% YoY Diluted EPS
$0.53
▼ 61.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
Alkermes plc. (ALKS) Q1 2024 Earnings Call Transcript
Positive tone
Proprietary product portfolio growth
LYBALVI launch trajectory and prescriber expansion
2024 financial guidance reiteration and outlook
Revenue
$350.37M
▲ 21.8% YoY Diluted EPS
$0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Alkermes plc. (ALKS) Q4 2023 Earnings Call Transcript
Confident tone
LYBALVI Commercial Performance
ALKS 2680 Orexin Pipeline
VIVITROL Growth and Mix
Revenue
$377.48M*
▲ 23.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-25
Alkermes plc. (ALKS) Q3 2023 Earnings Call Transcript
Revenue
$380.94M
▲ 51% YoY Diluted EPS
$0.28
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-26
Alkermes plc. (ALKS) Q2 2023 Earnings Call Transcript
Revenue
$617.40M
▲ 123.5% YoY Diluted EPS
$1.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-26
Alkermes plc. (ALKS) Q1 2023 Earnings Call Transcript
Revenue
$287.60M
▲ 3.2% YoY Diluted EPS
$-0.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-16
Alkermes plc. (ALKS) Q4 2022 Earnings Call Transcript
Revenue
$304.67M*
▼ 6.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Alkermes plc. (ALKS) Q3 2022 Earnings Call Transcript
Revenue
$252.36M
▼ 14.2% YoY Diluted EPS
$-0.39
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-27
Alkermes plc. (ALKS) Q2 2022 Earnings Call Transcript
Revenue
$276.22M
▼ 9.1% YoY Diluted EPS
$-0.18
▼ 1900% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-27
Alkermes plc. (ALKS) Q1 2022 Earnings Call Transcript
Revenue
$278.55M
▲ 10.8% YoY Diluted EPS
$-0.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-16
Alkermes plc. (ALKS) Q4 2021 Earnings Call Transcript
Revenue
$324.46M*
▲ 15.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-27
Alkermes plc. (ALKS) Q3 2021 Earnings Call Transcript
Revenue
$294.14M
▲ 11% YoY Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-28
Alkermes plc. (ALKS) Q2 2021 Earnings Call Transcript
Revenue
$303.72M
▲ 22.7% YoY Diluted EPS
$0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-28
Alkermes plc. (ALKS) Q1 2021 Earnings Call Transcript
Revenue
$251.43M
▲ 2.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-11
Alkermes plc. (ALKS) Q4 2020 Earnings Call Transcript
Revenue
$280.00M*
▼ 32.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Alkermes plc. (ALKS) Q3 2020 Earnings Call Transcript
Revenue
$265.01M
▲ 3.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-29
Alkermes plc. (ALKS) Q2 2020 Earnings Call Transcript
Revenue
$247.53M
▼ 11.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-29
Alkermes plc. (ALKS) Q1 2020 Earnings Call Transcript
Revenue
$246.22M
▲ 10.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-13
Alkermes plc. (ALKS) Q4 2019 Earnings Call
Revenue
$412.73M*
▲ 30.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 webcasts